Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CELZ
stocks logo

CELZ

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q3
FY2024Q4
FY2025Q2
0.00
-100%
--
--
0.00
-100%
--
--
0.00
-100%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Creative Medical Technology Holdings, Inc. (CELZ) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -32.93%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-32.93%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Creative Medical Technology Holdings Inc (CELZ.O) is -1.43, compared to its 5-year average forward P/E of -1.28. For a more detailed relative valuation and DCF analysis to assess Creative Medical Technology Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.28
Current PE
-1.43
Overvalued PE
0.85
Undervalued PE
-3.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1037.19
Current PS
0.00
Overvalued PS
3677.32
Undervalued PS
-1602.95
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CELZ News & Events

Events Timeline

(ET)
2025-12-02
09:30:00
Creative Medical Technology Receives WHO Approval for Olastrocel as INN for CELZ-201
select
2025-11-21 (ET)
2025-11-21
16:32:54
Creative Medical to Offer 2.79 Million Shares of Common Stock for Shareholders
select
2025-10-30 (ET)
2025-10-30
09:19:59
Creative Medical Introduces Veterans Initiative for Biodefense Inc.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-02Newsfilter
Creative Medical Secures WHO Approval for Olastrocel, Enhancing Global Development Prospects
  • Global Recognition: Creative Medical Technology's active cellular substance in CELZ-201 has been officially named 'olastrocel' by the WHO, marking a significant advancement in the clinical stage and expected to enhance its recognition and acceptance in international markets.
  • Strategic Importance: The assignment of the WHO-recognized International Non-Proprietary Name (INN) provides a unified scientific identity for the product, facilitating regulatory clarity and improving development efficiency across jurisdictions, thereby accelerating market entry to meet urgent global demand for innovative therapies.
  • Market Opportunities: Creative Medical focuses on treating chronic lower back pain, diabetes, and other conditions, with market opportunities reaching billions of dollars, and the development of olastrocel will strongly support the company's competitiveness in these high-demand areas.
  • Clinical Progress: Coupled with the FDA's Fast Track designation for olastrocel in degenerative disc disease, Creative Medical's clinical strategy is set to bolster investor confidence and propel the company toward its next clinical milestones.
[object Object]
Preview
3.5
12-02Globenewswire
Creative Medical Secures WHO Approval for Olastrocel Name, Enhancing Global Development
  • Global Recognition: Creative Medical's CELZ-201 cell therapy has received approval from the World Health Organization (WHO) for the name 'olastrocel', marking a significant milestone in global development and enhancing its recognition in international markets.
  • Clinical Strategy Advancement: CEO Timothy Warbington stated that the WHO-recognized INN provides a unified scientific identity for olastrocel, facilitating clinical adoption and long-term scalability in large markets, thereby laying a solid foundation for the company's future clinical strategy.
  • Market Opportunities: Olastrocel targets multiple therapeutic areas, including chronic lower back pain and diabetes, representing multi-billion-dollar market opportunities, indicating the therapy's significant potential in addressing unmet medical needs.
  • Investor Confidence: With the FDA Fast Track designation secured, Creative Medical's progress is viewed as disciplined, strengthening the foundation for the olastrocel platform and expected to drive the company's success in upcoming clinical catalysts.
[object Object]
Preview
5.0
10-30Newsfilter
Creative Medical Technology Holdings, Inc. Launches Innovative Regenerative BioDefense Program for U.S. Veterans Affected by Burn Pits

  • Launch of BioDefense Inc. Veterans Initiative: Creative Medical Technology Holdings has launched a national program aimed at addressing the long-term health effects of toxic burn pit exposure among U.S. veterans, utilizing advanced regenerative technologies and AI analytics.

  • Partnership with Greenstone Biosciences: The initiative includes a collaboration with Greenstone Biosciences to leverage AI and iPSC technology for developing predictive models and regenerative therapies for veterans affected by toxic exposure.

  • Creation of a Molecular Database: The program will establish a comprehensive molecular-level database of veteran toxic exposure, which will serve as a foundation for precision medicine in diagnosing and treating related health issues.

  • National Health Security Initiative: Through this initiative, Creative Medical aims to integrate biotechnology and AI into a new national biodefense strategy, enhancing health security for both military and civilian populations.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Creative Medical Technology Holdings Inc (CELZ) stock price today?

The current price of CELZ is 2.22 USD — it has increased 0.41 % in the last trading day.

arrow icon

What is Creative Medical Technology Holdings Inc (CELZ)'s business?

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.

arrow icon

What is the price predicton of CELZ Stock?

Wall Street analysts forecast CELZ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CELZ is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Creative Medical Technology Holdings Inc (CELZ)'s revenue for the last quarter?

Creative Medical Technology Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Creative Medical Technology Holdings Inc (CELZ)'s earnings per share (EPS) for the last quarter?

Creative Medical Technology Holdings Inc. EPS for the last quarter amounts to -0.48 USD, decreased -36.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Creative Medical Technology Holdings Inc (CELZ)'s fundamentals?

The market is revising No Change the revenue expectations for Creative Medical Technology Holdings, Inc. (CELZ) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -32.93%.
arrow icon

How many employees does Creative Medical Technology Holdings Inc (CELZ). have?

Creative Medical Technology Holdings Inc (CELZ) has 4 emplpoyees as of December 05 2025.

arrow icon

What is Creative Medical Technology Holdings Inc (CELZ) market cap?

Today CELZ has the market capitalization of 5.71M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free